Stock vs Stock Comparison

CorMedix Inc. vs Johnson & Johnson

CRMD wins the Tale of the Tape 6–3.

CRMD
JNJ$223.24

🏆 Tale of the Tape

63
CRMDJNJ
52.3%Profitability (Net Margin)28.5%
3.9xValuation (P/E)26.1x
18.5%Efficiency (ROIC)18.3%
5/9Health (Piotroski F)4/9
Safety (Altman Z)4.0
617.0%Growth (Rev YoY)6.0%
Risk (Sharpe 1Y)2.69
1.04xBalance Sheet (D/E)1.44x
FCF Yield3.25%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Fundamentals

MetricCRMDJNJ
Market Cap$0.6B$542.4B
P/E Ratio3.9x26.1x
Forward P/E11.0x17.7x
P/B1.55x6.68x
Dividend Yield2.38%
Beta1.460.26

Quantitative Metrics

MetricCRMDJNJ
DCF Fair Value$34.92$134.24
DCF Upside-43.6%
Piotroski F5/94/9
Altman Z3.97
Beneish M15.29-2.27
FCF Yield3.25%
Net Debt/EBITDA-0.0x0.5x
ROIC18.5%18.3%
WACC7.7%
ROIC – WACC10.5pp
Gross Margin88.5%67.9%
Net Margin52.3%28.5%
Rev Growth YoY617.0%6.0%
Sharpe (1Y)2.69
Max Drawdown 3Y-16.0%
FCF Payout Ratio64%

CRMD Price

Loading chart...

JNJ Price

Loading chart...

ETF Exposure

CRMD found in:

XPH1.38%
VHT0.01%

JNJ found in:

XLV10.42%
IYH10.14%
VHT8.84%
HDV6.84%
MTUM3.76%
DIA2.83%
MGV2.75%
DGRO2.64%
VIG2.49%
VYM2.30%
VTV2.16%
DGRW2.02%
SCHV2.02%
IWD1.94%
QUS1.81%
XPH1.74%
VONV1.69%
NOBL1.58%
VFMV1.42%
VFMO1.02%
SCHX0.96%
SPYG0.94%
SDY0.93%
VOO0.90%
SCHB0.90%
SPY0.87%
IVV0.85%
VONE0.84%
SPTM0.81%
VTI0.80%
SPYV0.79%
SPLG0.76%
ITOT0.75%
URTH0.70%
ACWI0.57%
VT0.49%
RSP0.21%
VFVA0.15%
ONEO0.05%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

CRMD vs JNJ: Head-to-Head Analysis

CorMedix Inc. (CRMD) and Johnson & Johnson (JNJ) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, CRMD leads 6–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, CRMD generates a return on invested capital (ROIC) of 18.5% compared to JNJ's 18.3%. This suggests CRMD is more effective at deploying capital to generate shareholder returns.

CRMD appears in 2 ETFs tracked by SecuritiesDB, while JNJ appears in 39 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, CRMD or JNJ?

Our quantitative analysis compares CRMD and JNJ across nine fundamental dimensions. CRMD wins the Tale of the Tape 6–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are CRMD and JNJ correlated?

Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.